Eprazinone (dihydrochloride)

Eprazinone dihydrochloride is a gent with mucolytic, secretolytic, antitussive, and bronchial antispasmodic properties. Eprazinone dihydrochloride is a neurokinin 1 receptor (NK1R) ligand. Eprazinone dihydrochloride has the potential for chronic bronchitis treatment that improved pulmonary function and arterial partial pressure of oxygen[1][2].

Product Specifications

CAS Number

[10402-53-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Neurokinin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/eprazinone-dihydrochloride.html

Purity

99.31

Solubility

DMSO : 6.25 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : ≥ 25 mg/mL

Smiles

O=C(C1=CC=CC=C1)C(C)CN2CCN(CC(OCC)C3=CC=CC=C3)CC2.Cl[H].Cl[H]

Molecular Formula

C24H34Cl2N2O2

Molecular Weight

453.45

Precautions

H302, H315, H319, H335

References & Citations

[1]R S Thrall, et al. Eprazinone Alters Lung Lavage Lipid Levels and Transtracheal Ion Transport. Exp Lung Res. May-Jun 1992;18 (3) :409-20.|[2]Yvonne Krautscheid, et al. Pharmacophore Modeling, Virtual Screening, and in Vitro Testing Reveal Haloperidol, Eprazinone, and Fenbutrazate as Neurokinin Receptors Ligands. J Chem Inf Model. 2014 Jun 23;54 (6) :1747-57.